Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074471 | 1.00 | CTSC (0.61) | CTSCKCNH2 | |
| SCHEMBL2075395 | 0.90 | CTSC (0.63) | CTSCKCNH2 | |
| SCHEMBL2075394 | 0.90 | CTSC (0.63) | CTSCKCNH2 | |
| SCHEMBL2072010 | 0.90 | CTSC (0.66) | CTSCKCNH2 | |
| SCHEMBL30738907 | 0.89 | CTSC (0.58) | CTSCKCNH2 | |
| SCHEMBL7858106 | 0.89 | CTSC (0.64) | CTSCKCNH2 | |
| SCHEMBL12422472 | 0.89 | CTSC (0.47) | CTSCKCNH2 | |
| SCHEMBL30738945 | 0.89 | CTSC (0.58) | CTSCKCNH2 | |
| SCHEMBL30738854 | 0.89 | CTSC (0.58) | CTSCKCNH2 | |
| SCHEMBL2073323 | 0.88 | CTSC (0.46) | CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306042-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | CTSC 3209/4885KCNH2 2084/4885 |
| US-20110201581-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | CTSC 3209/4885KCNH2 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.